Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to increase muscle mass and function but most showed limited efficacy. Here we show that the expression of components of the myos...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariot, Virginie, Joubert, Romain, Hourdé, Christophe, Féasson, Léonard, Hanna, Michael, Muntoni, Francesco, Maisonobe, Thierry, Servais, Laurent, Bogni, Caroline, Le Panse, Rozen, Benvensite, Olivier, Stojkovic, Tanya, Machado, Pedro M., Voit, Thomas, Buj-Bello, Ana, Dumonceaux, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709430/
https://www.ncbi.nlm.nih.gov/pubmed/29192144
http://dx.doi.org/10.1038/s41467-017-01486-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709430/
https://www.ncbi.nlm.nih.gov/pubmed/29192144
http://dx.doi.org/10.1038/s41467-017-01486-4

Ejemplares similares